## => d his

(FILE 'HOME' ENTERED AT 11:00:42 ON 29 APR 2004)

FILE 'REGISTRY' ENTERED AT 11:00:58 ON 29 APR 2004 STRUCTURE UPLOADED L1 L2 23 S L1 L3 STRUCTURE UPLOADED

14 S L3 T.4 368 S L3 SSS FULL L5

FILE 'CAPLUS' ENTERED AT 11:04:17 ON 29 APR 2004 L6 11 S L5

=> d 13

L3 HAS NO ANSWERS

STR L3

Structure attributes must be viewed using STN Express query preparation.

## => d 1-11 bib abs hitstr

L6 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN

2003:892446 CAPLUS AN

139:364934 DN

Preparation of aryl ether substituted imidazoquinolines as immune response TΙ modifiers

Heppner, Philip D.; Charles, Leslie J.; Dellaria, Joseph F.; Merrill, IN Bryon A.; Mickelson, John W.

3M Innovative Properties Co., USA PΑ

U.S. Pat. Appl. Publ., 97 pp., Cont.-in-part of U.S. Ser. No. 13,202. so CODEN: USXXCO

DTPatent

LA English FAN.CNT 11					
1744.	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ΡI	US 2003212092	A1	20031113		20020607
	US 6677348	B2	20040113		
	US 2003212091	A1	20031113	US 2001-13202	20011206
	US 6670372	В2	20031230		
	US 2004072858	A1	20040415	US 2003-675833	20030930
PRAI	US 2000-254218P	P	20001208		
	US 2001-13202	A2	20011206		
	US 2001-11921	A1	20011206		
OS GI	MARPAT 139:36493	4			
0.1					

Complete report in 10/696753

$$NH_2$$
 $N$ 
 $R^2$ 
 $X-O-R^1$ 

The title compds. [I; X = (CH2)2, CHEtCH2, etc.; R1 = alkenyl, aryl, R4-aryl; R2 = H, alkyl, alkenyl, etc.; R4 = alkyl, alkenyl which may be interrupted by one or more O atoms; R3 = H, alkyl; n = 0-4; R = alkyl, alkoxy, OH, etc.] that contain ether and aryl or alkenyl functionality at the 1-position, and are useful as immune response modifiers, were prepared E.g., a multi-step synthesis of I [X = (CH2)2; R1 = CH2C.tplbond.CH; R2 = H; n = 0] which showed the lowest effective concentration of 0.12  $\mu\text{M}$  and 1.11  $\mu\text{M}$  to induce biosynthesis of interferon  $\alpha$  and TNF $\alpha$  in human cells, resp., was given. The compds. I can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases. The pharmaceutical composition comprising the compound I is claimed.

T 437602-85-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of aryl ether substituted imidazoquinolines as immune response modifiers).

RN 437602-85-2 CAPLUS

CN 1H-Imidazo[4,5-c]quinolin-4-amine, 2-octyl-1-[2-[(3-phenyl-2-propynyl)oxy]ethyl]- (9CI) (CA INDEX NAME)